Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting

NEW YORK, June 24, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American Diabetes Association annual meeting.

The presentations were made in part by members of Islet's Scientific Advisory Board, which included Dr. Jonathan Lakey, Dr. Kevan Harold and Dr. Eitan Akirav.   Sessions presented by Islet highlighted the following: 1) Circulating demethylated insulin as a potential early indicator of beta cell loss, 2) Immune therapy and type one diabetes previously discussed in the ADA journal 'Diabetes,' 3) New inhibitors to preserve and protect islet function, 4) Prolonged Euglycemia following transplantation of alginate encapsulated porcine islet cells, and 5) Consistency and scalability of young porcine islet isolation.

"We are excited to see that our technologies were accepted for presentation at the American Diabetes Association's annual meeting," said John Steel, Chairman and Chief Executive Officer of Islet Sciences. "This clearly provides further evidence for the value and promise for these technologies to be developed for treatments for diabetes and related complications."

"The technologies we have developed are groundbreaking and the recognition we continue to see from such well respected organizations such as the American Diabetes Association is extremely validating," stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. The presentation of these technologies are another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community."

The technologies presented at the ADA meeting have received grant support from Department of Defense, National Institute of Health, Juvenile Diabetes Research Foundation, as well as funding from Islet Sciences. 

About Islet Sciences, Inc.


Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes.  The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti-inflammatory compounds. For more information: www.isletsciences.com

Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson

ProActive Capital Group
646-863-6341
jramson@proactivecapital.com

Media Contact:
Sandra Lee
ProActive Capital Group
646-863-6341
slee@proactivecapital.com

SOURCE Islet Sciences, Inc.



RELATED LINKS
http://www.isletsciences.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.